BTIG analyst Mark Massaro raised the firm’s price target on Natera (NTRA) to $2 10 from $200 and keeps a Buy rating on the shares. The firm is positive on Natera following the company’s call with the lead principal investigator of the IMvigor011 trial, a randomized, double-blind, phase III study in muscle-invasive bladder cancer. The study was recently presented in a Presidential Symposium at ESMO in Berlin, Germany, and published in the New England Journal of Medicine. BTIG says ESMO studies may elevate the company’s Signatera and the MRD field to a new level, and that it expects clinician and biopharma activity to pick up from here. Natera remains a Top Pick, the firm adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera reports results from IMvigor011 clinical trial
- DE, RKLB, NTRA, QSI: Cathie Wood Loads Up on Deere and ATAI, Trims Stakes in Rocket Lab and Biotech Stocks
- Natera to present 14 studies to be presented at ESMO Congress
- Natera enrolls over 1,600 patients in EXPAND trial
- Natera announces publication of Signatera validation study